vs

Side-by-side financial comparison of Charles River Laboratories (CRL) and SBA Communications (SBAC). Click either name above to swap in a different company.

Charles River Laboratories is the larger business by last-quarter revenue ($994.2M vs $703.4M, roughly 1.4× SBA Communications). SBA Communications runs the higher net margin — 26.3% vs -27.8%, a 54.1% gap on every dollar of revenue. On growth, Charles River Laboratories posted the faster year-over-year revenue change (-0.8% vs -1.6%). Over the past eight quarters, SBA Communications's revenue compounded faster (3.2% CAGR vs -0.9%).

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.

SBA Communications Corporation is a real estate investment trust which owns and operates wireless infrastructure in the United States, Canada, Central America, South America, and South Africa. It was founded in 1989 as Steven Bernstein and Associates by Steven Bernstein.

CRL vs SBAC — Head-to-Head

Bigger by revenue
CRL
CRL
1.4× larger
CRL
$994.2M
$703.4M
SBAC
Growing faster (revenue YoY)
CRL
CRL
+0.7% gap
CRL
-0.8%
-1.6%
SBAC
Higher net margin
SBAC
SBAC
54.1% more per $
SBAC
26.3%
-27.8%
CRL
Faster 2-yr revenue CAGR
SBAC
SBAC
Annualised
SBAC
3.2%
-0.9%
CRL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CRL
CRL
SBAC
SBAC
Revenue
$994.2M
$703.4M
Net Profit
$-276.6M
$184.9M
Gross Margin
Operating Margin
-28.5%
48.7%
Net Margin
-27.8%
26.3%
Revenue YoY
-0.8%
-1.6%
Net Profit YoY
-28.9%
-15.1%
EPS (diluted)
$-5.57
$1.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRL
CRL
SBAC
SBAC
Q1 26
$703.4M
Q4 25
$994.2M
$719.6M
Q3 25
$1.0B
$732.3M
Q2 25
$1.0B
$699.0M
Q1 25
$984.2M
$664.2M
Q4 24
$1.0B
$693.7M
Q3 24
$1.0B
$667.6M
Q2 24
$1.0B
$660.5M
Net Profit
CRL
CRL
SBAC
SBAC
Q1 26
$184.9M
Q4 25
$-276.6M
$370.4M
Q3 25
$54.4M
$236.8M
Q2 25
$52.3M
$225.8M
Q1 25
$25.5M
$220.7M
Q4 24
$-214.5M
$178.8M
Q3 24
$69.7M
$258.5M
Q2 24
$94.1M
$162.8M
Gross Margin
CRL
CRL
SBAC
SBAC
Q1 26
Q4 25
75.6%
Q3 25
74.1%
Q2 25
75.4%
Q1 25
76.9%
Q4 24
78.1%
Q3 24
34.6%
77.5%
Q2 24
34.5%
78.6%
Operating Margin
CRL
CRL
SBAC
SBAC
Q1 26
48.7%
Q4 25
-28.5%
41.5%
Q3 25
13.3%
51.1%
Q2 25
9.7%
47.9%
Q1 25
7.6%
50.4%
Q4 24
-16.7%
55.1%
Q3 24
11.6%
56.3%
Q2 24
14.8%
53.7%
Net Margin
CRL
CRL
SBAC
SBAC
Q1 26
26.3%
Q4 25
-27.8%
51.5%
Q3 25
5.4%
32.3%
Q2 25
5.1%
32.3%
Q1 25
2.6%
33.2%
Q4 24
-21.4%
25.8%
Q3 24
6.9%
38.7%
Q2 24
9.2%
24.7%
EPS (diluted)
CRL
CRL
SBAC
SBAC
Q1 26
$1.74
Q4 25
$-5.57
$3.47
Q3 25
$1.10
$2.20
Q2 25
$1.06
$2.09
Q1 25
$0.50
$2.04
Q4 24
$-4.17
$1.61
Q3 24
$1.33
$2.40
Q2 24
$1.74
$1.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRL
CRL
SBAC
SBAC
Cash + ST InvestmentsLiquidity on hand
$213.8M
$269.1M
Total DebtLower is stronger
$2.1B
$2.7B
Stockholders' EquityBook value
$3.2B
Total Assets
$7.1B
$11.7B
Debt / EquityLower = less leverage
0.68×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRL
CRL
SBAC
SBAC
Q1 26
$269.1M
Q4 25
$213.8M
$271.2M
Q3 25
$207.1M
$431.1M
Q2 25
$182.8M
$276.8M
Q1 25
$229.4M
$702.2M
Q4 24
$194.6M
$444.4M
Q3 24
$210.2M
$202.6M
Q2 24
$179.2M
$250.9M
Total Debt
CRL
CRL
SBAC
SBAC
Q1 26
$2.7B
Q4 25
$2.1B
$12.9B
Q3 25
$2.2B
$12.7B
Q2 25
$2.3B
$12.5B
Q1 25
$2.5B
$12.4B
Q4 24
$2.2B
$13.6B
Q3 24
$2.3B
$12.3B
Q2 24
$2.4B
$12.3B
Stockholders' Equity
CRL
CRL
SBAC
SBAC
Q1 26
Q4 25
$3.2B
$-4.9B
Q3 25
$3.4B
$-4.9B
Q2 25
$3.4B
$-4.9B
Q1 25
$3.2B
$-5.0B
Q4 24
$3.5B
$-5.1B
Q3 24
$3.8B
$-5.2B
Q2 24
$3.7B
$-5.3B
Total Assets
CRL
CRL
SBAC
SBAC
Q1 26
$11.7B
Q4 25
$7.1B
$11.6B
Q3 25
$7.5B
$11.3B
Q2 25
$7.6B
$10.8B
Q1 25
$7.6B
$10.4B
Q4 24
$7.5B
$11.4B
Q3 24
$8.0B
$10.2B
Q2 24
$7.9B
$9.8B
Debt / Equity
CRL
CRL
SBAC
SBAC
Q1 26
Q4 25
0.68×
Q3 25
0.64×
Q2 25
0.70×
Q1 25
0.79×
Q4 24
0.65×
Q3 24
0.62×
Q2 24
0.65×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRL
CRL
SBAC
SBAC
Operating Cash FlowLast quarter
$147.5M
$255.1M
Free Cash FlowOCF − Capex
$58.6M
FCF MarginFCF / Revenue
5.9%
Capex IntensityCapex / Revenue
8.9%
9.5%
Cash ConversionOCF / Net Profit
1.38×
TTM Free Cash FlowTrailing 4 quarters
$518.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRL
CRL
SBAC
SBAC
Q1 26
$255.1M
Q4 25
$147.5M
$1.3B
Q3 25
$213.8M
$318.0M
Q2 25
$204.6M
$368.1M
Q1 25
$171.7M
$301.2M
Q4 24
$159.4M
$1.3B
Q3 24
$251.8M
$304.7M
Q2 24
$193.5M
$425.6M
Free Cash Flow
CRL
CRL
SBAC
SBAC
Q1 26
Q4 25
$58.6M
$833.3M
Q3 25
$178.2M
$258.0M
Q2 25
$169.3M
$312.2M
Q1 25
$112.4M
$255.0M
Q4 24
$83.7M
$1.2B
Q3 24
$213.1M
$239.9M
Q2 24
$154.0M
$375.6M
FCF Margin
CRL
CRL
SBAC
SBAC
Q1 26
Q4 25
5.9%
115.8%
Q3 25
17.7%
35.2%
Q2 25
16.4%
44.7%
Q1 25
11.4%
38.4%
Q4 24
8.4%
179.9%
Q3 24
21.1%
35.9%
Q2 24
15.0%
56.9%
Capex Intensity
CRL
CRL
SBAC
SBAC
Q1 26
9.5%
Q4 25
8.9%
63.7%
Q3 25
3.5%
8.2%
Q2 25
3.4%
8.0%
Q1 25
6.0%
7.0%
Q4 24
7.5%
12.6%
Q3 24
3.8%
9.7%
Q2 24
3.8%
7.6%
Cash Conversion
CRL
CRL
SBAC
SBAC
Q1 26
1.38×
Q4 25
3.49×
Q3 25
3.93×
1.34×
Q2 25
3.91×
1.63×
Q1 25
6.74×
1.36×
Q4 24
7.47×
Q3 24
3.61×
1.18×
Q2 24
2.06×
2.61×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRL
CRL

Discovery And Safety Assessment Segment$591.6M60%
Manufacturing Support Segment$196.4M20%
Transferred At Point In Time$108.0M11%
Transferred Over Time$98.3M10%

SBAC
SBAC

Site leasing$656.1M93%
Site development$47.3M7%

Related Comparisons